An Act To Promote Prescription Drug Price Transparency
Sec. 1. 22 MRSA §2698, as enacted by PL 1999, c. 786, Pt. A, §3, is repealed and the following enacted in its place:
§ 2698. Investigation by Attorney General
(1) The wholesale acquisition cost is $2,500 or more annually or for a course of treatment;
(2) The wholesale acquisition cost of the drug has increased by 50% or more over the previous 5 years; or
(3) The wholesale acquisition cost of the drug has increased by 15% or more over the previous 12 months.
This bill amends the law governing profiteering in prescription drugs. The bill requires more disclosure of drug production, research and development costs, marketing and advertising costs and actual costs paid upon purchase. The bill allows investigations by the Attorney General of violations of these provisions. The bill adds a required written report from the Attorney General each year.